Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00443677

Acronym

HD2000

Enrollment

307

Registered

2007-03-06

Start date

2000-04-30

Completion date

2007-06-30

Last updated

2009-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Hodgkin Disease

Brief summary

The purpose of this study is to compare the toxicities of the COPPEBVCAD vs BEACOPP vs ABVD regimens.

Interventions

DRUGCOPPEBVCAD vs BEACOPP vs ABVD

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Histologically confirmed diagnosis of Hodgkin disease * Clinical stage IIB, III, IV * No prior treatment for Hodgkin disease or other malignancy * Age 18-65 year * Good cardiac, pulmunar, renal and hepatic function * Performance status 0-3 (Karnofsky 100- 40) * Written Informed Consent

Exclusion criteria

* HIV positivity * Large cell, anaplastic, CD30+ lymphoma

Design outcomes

Primary

Measure	Time frame
To compare the toxicity of the COPPEBVCAD vs BEACOPP vs ABVD regimens	—

Secondary

Measure	Time frame
To compare the results in terms of response, failure free survival and relapse free survival of the three regimens	—

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026